Anacor Pharmaceuticals Announces Presentations of Crisaborole Topical Ointment, 2% Phase 3 Pivotal Data at Two Upcoming Medical Conferences

PALO ALTO, Calif.–(BUSINESS WIRE)–Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that data
from the Phase 3 pivotal studies of investigational drug Crisaborole
Topical Ointment, 2% will be presented at two upcoming medical meetings.

The Fall Clinical Dermatology Conference, October 1-4, 2015 in Las
Vegas, Nevada

  • The following abstracts have recently been accepted for poster

    • “Results from Two Phase 3 Studies in Children and Adults with
      Mild to Moderate Atopic Dermatitis Treated with Crisaborole
      Topical Ointment, 2%, a Novel Nonsteroidal, Topical
      Anti-Inflammatory, Phosphodiesterase 4 Inhibitor”
    • “Evaluation of Pruritus and Signs of Atopic Dermatitis With
      Crisaborole Topical Ointment, 2%, a Novel Nonsteroidal, Topical
      Anti-Inflammatory, Phosphodiesterase 4 Inhibitor in Two Phase 3
      Studies in Children and Adults With Mild to Moderate Atopic

The 24th European Academy of Dermatology and
Venereology Congress, October 7-11, 2015 in Copenhagen, Denmark

  • LATCOP-0093, “Treatment of children and adults with mild to
    moderate atopic dermatitis with Crisaborole Topical Ointment, 2%, a
    novel, nonsteroidal, topical anti-inflammatory, phosphodiesterase 4
    inhibitor: results from two phase 3 studies”
    will be presented
    during the late breaking news session on Saturday, October 10, between
    8:00 a.m. and 11:15 a.m. CEST by Mark Lebwohl, M.D., Sol and Clara
    Kest Professor and Chair of the Department of Dermatology at the Icahn
    School of Medicine at Mount Sinai.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing
and commercializing novel small-molecule therapeutics derived from its
boron chemistry platform. Anacor’s first approved drug, KERYDIN®
(tavaborole) topical solution, 5%, is an oxaborole antifungal approved
by the U.S. Food and Drug Administration in July 2014 for the topical
treatment of onychomycosis of the toenails. In July 2014, Anacor entered
into an exclusive agreement with Sandoz Inc., a Novartis company,
pursuant to which PharmaDerm, the branded dermatology division of
Sandoz, distributes and commercializes KERYDIN in the United States. In
September 2014, PharmaDerm launched KERYDIN in the United States.
Anacor’s lead product development candidate is crisaborole topical
ointment, 2%, a novel non-steroidal topical anti-inflammatory PDE-4
inhibitor in development for the potential treatment of mild-to-moderate
atopic dermatitis and psoriasis. Beyond KERYDIN and crisaborole, Anacor
has discovered three investigational compounds that it has out-licensed
for further development. The first compound is licensed to Eli Lilly and
Company for the potential treatment of an animal health indication. The
second compound, AN5568, also referred to as SCYX-7158, is licensed to
Drugs for Neglected Diseases initiative for the potential treatment of
human African trypanosomiasis. The third compound is licensed to
GlaxoSmithKline LLC for development in tuberculosis. Anacor also has a
pipeline of other internally discovered topical and systemic boron-based
compounds in early stages of research and development. These include
AN3365, an investigational Gram-negative antibiotic, and certain other
wholly-owned investigational product candidates. For more information,


Anacor Pharmaceuticals, Inc.
DeDe Sheel
Senior Director,
Investor Relations and Corporate Communications